Literature DB >> 12376321

Effects of fasting and glucocorticoids on hepatic gluconeogenesis assessed using two independent methods in vivo.

Richard E Goldstein1, Luciano Rossetti, Brett A J Palmer, Rong Liu, Duna Massillon, Melanie Scott, Doss Neal, Phillip Williams, Benjamin Peeler, Alan D Cherrington.   

Abstract

The purpose of this study was to compare the assessment of gluconeogenesis (GNG) in the overnight- and prolonged-fasted states and during chronic hypercortisolemia using the arteriovenous difference and [14C]phosphoenolpyruvate-liver biopsy techniques as well as a combination of the two. Two weeks before a study, catheters and flow probes were implanted in the hepatic and portal veins and femoral artery of dogs. Animals were studied after an 18-h fast (n = 8), a 42- or 66-h fast (n = 7), and an 18-h fast plus a continuous infusion of cortisol (3.0 microg. kg(-1). min(-1)) for 72 h (n = 7). Each experiment consisted of an 80-min tracer ([3-(3)H]glucose and [U-(14)C]alanine) and dye equilibration period (-80 to 0 min) and a 45-min sampling period. In the cortisol-treated group, plasma cortisol increased fivefold. In the overnight-fasted group, total GNG flux rate (GNG(flux)), conversion of glucose 6-phosphate to glucose (GNG(G-6-P-->Glc)), glucose cycling, and maximal GNG flux rate (GNG(max)) were 0.95 +/- 0.14, 0.65 +/- 0.06, 0.62 +/- 0.06, and 0.70 +/- 0.09 mg. kg(-1). min(-1), respectively. In the prolonged-fasted group, they were 1.50 +/- 0.18, 1.18 +/- 0.13, 0.40 +/- 0.07, and 1.28 +/- 0.10 mg. kg(-1). min(-1), whereas in the cortisol-treated group they were 1.64 +/- 0.33, 0.99 +/- 0.29, 1.32 +/- 0.24, and 0.91 +/- 0.13 mg. kg(-1). min(-1). These results demonstrate that GNG(G-6-P-->Glc) and GNG(max) were almost identical. However, these rates were 15-38% lower than GNG(flux) generated by a combination of the two methods. This difference was most apparent in the steroid-treated group, where the combination of the two methods (GNG(flux)) detected a significant increase in gluconeogenic flux.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12376321     DOI: 10.1152/ajpendo.00320.2002

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  6 in total

1.  Molecular characterization of insulin-mediated suppression of hepatic glucose production in vivo.

Authors:  Christopher J Ramnanan; Dale S Edgerton; Noelia Rivera; Jose Irimia-Dominguez; Ben Farmer; Doss W Neal; Margaret Lautz; E Patrick Donahue; Catalina M Meyer; Peter J Roach; Alan D Cherrington
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

2.  Impact of a glycogen phosphorylase inhibitor and metformin on basal and glucagon-stimulated hepatic glucose flux in conscious dogs.

Authors:  Tracy P Torres; Noriyasu Sasaki; E Patrick Donahue; Brooks Lacy; Richard L Printz; Alan D Cherrington; Judith L Treadway; Masakazu Shiota
Journal:  J Pharmacol Exp Ther       Date:  2011-03-01       Impact factor: 4.030

3.  Effects of insulin on the metabolic control of hepatic gluconeogenesis in vivo.

Authors:  Dale S Edgerton; Christopher J Ramnanan; Carrie A Grueter; Kathryn M S Johnson; Margaret Lautz; Doss W Neal; Phillip E Williams; Alan D Cherrington
Journal:  Diabetes       Date:  2009-09-15       Impact factor: 9.461

4.  Modulation in Wistar rats of blood corticosterone compartmentation by sex and a cafeteria diet.

Authors:  María del Mar Romero; Fredrik Holmgren-Holm; Maria del Mar Grasa; Montserrat Esteve; Xavier Remesar; José Antonio Fernández-López; Marià Alemany
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

5.  Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.

Authors:  J Michael Gaziano; Anthony H Cincotta; Aaron Vinik; Lawrence Blonde; Nancy Bohannon; Richard Scranton
Journal:  J Am Heart Assoc       Date:  2012-10-25       Impact factor: 5.501

6.  Urinary and Serum Metabolomics Analyses Uncover That Total Glucosides of Paeony Protect Liver against Acute Injury Potentially via Reprogramming of Multiple Metabolic Pathways.

Authors:  Haojie Li; Wenli Cao; Mengxi Lu; Chunxiao Wu; Xinguo Wang; Liying Niu
Journal:  Evid Based Complement Alternat Med       Date:  2017-12-11       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.